- Home
- CR vs PCVX Comparison
CR vs PCVX Comparison
Compare CR & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CR | PCVX |
|---|---|---|
| Founded | 1855 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0B | 8.4B |
| IPO Year | 2022 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CR | PCVX |
|---|---|---|
| Price | $175.12 | $60.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $223.40 | $98.33 |
| AVG Volume (30 Days) | 385.0K | ★ 1.1M |
| Earning Date | 04-27-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.59% | N/A |
| EPS Growth | ★ 23.96 | N/A |
| EPS | ★ 6.26 | N/A |
| Revenue | ★ $2,305,000,000.00 | N/A |
| Revenue This Year | $28.11 | N/A |
| Revenue Next Year | $5.76 | N/A |
| P/E Ratio | $27.56 | ★ N/A |
| Revenue Growth | ★ 8.16 | N/A |
| 52 Week Low | $130.66 | $28.09 |
| 52 Week High | $214.31 | $65.00 |
Technical Indicators
Market Signals| Indicator | CR | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 46.32 | 62.10 |
| Support Level | $159.58 | $42.30 |
| Resistance Level | $185.01 | $65.00 |
| Average True Range (ATR) | 6.16 | 2.19 |
| MACD | 0.95 | 0.55 |
| Stochastic Oscillator | 77.17 | 93.58 |
Price Performance
Historical ComparisonAbout CR Crane Company
Crane is a diversified industrial firm that manufactures a broad range of products, including valves, pumps, aerospace components, and fiberglass-reinforced plastic panels. Its business is organized into two segments: aerospace and advanced technologies, and process flow technologies. Crane generated approximately $2.3 billion in revenue in 2025.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.